EGFR and hepatocellular carcinoma: New molecular therapies for HCC include epidermal growth factor receptor (EGFR) inhibitors, for instance, gefitinib, erlotinib [16, 17], cetuximab [18–21], and antiangiogenic compounds, such as bevacizumab [22, 23] and sunitinib [24].